Keywords
age classes
carriage
Abstract
Notwithstanding different meningococcal serogroups have changed their distribution and their impact in different age classes over time, N. meningitidis' invasive diseases are a major public health issue worldwide, due to the related complications and severe sequelae. Nowadays, the highest rates of invasive disease are registered in children younger than 1 year of age, with a second lesser peak in adolescents and young adults (15-25 years of age). On the contrary, the prevalence of carriage is low in newborns and in school-age children, and increases during adolescence and young-adult age; then it decreases again in older age. N. meningitidis' infection prevalence has greatly decreased in Europe and North America thanks to the use of conjugate vaccines (Men C and MenACWY) as well as the incidence of invasive disease due to serogroup A in sub-saharian Africa after the introduction of MenAfriVac conjugate vaccine.
The great success of conjugate vaccines is related not only to the direct protection from disease but also to the impact on carriage; this latter allows an indirect protection of unimmunized subjects. For these reasons, the implementation of immunization with the new generation vaccines in the age classes most impacted by disease and carriage (first year of life, adolescence and young adulthood) could permit to achieve an extraordinary decrease of the incidence of meningococcal disease.
References
Vernikos G, Medini D. Bexsero® chronicle. Pathog Glob Health 2014;108(7):305-316. Available from: http://europepmc.org/abstract/MED/25417906 PubMed PMID: 25417906. doi: 10.1179/2047773214Y.0000000162. [Google Scholar]
Gasparini R, Amicizia D, Lai PL, Panatto D. Neisseria meningitidis, pathogenetic mechanisms to overcome the human immune defences.. J Prev Med Hyg 2012;53(2):50-55. Available from: http://www.diseaseinfosearch.org/result/5121 PubMed PMID: 23240160. [Google Scholar]
Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, et al. The changing and dynamic epidemiology of meningococcal disease.. Vaccine 2011 Dec;30 Suppl 2. Available from: https://www.nlm.nih.gov/medlineplus/meningococcalinfections.html PubMed PMID: 22178525. doi: 10.1016/j.vaccine.2011.12.032. [Google Scholar]
World Health Organization (WHO) , author . Meningococcal vaccines: WHO position paper. November 2011. Wkly Epidemiol Rec 2011;86(47):521-539. Available from: http://www.who.int/wer/2011/wer8647.pdf?ua=1 PubMed PMID: 22128384. [Google Scholar]
Stephens DS, Hoffman LH, McGee ZA. Interaction of Neisseria meningitidis with human nasopharyngeal mucosa: attachment and entry into columnar epithelial cells.. J Infect Dis 1983;148(3):369-376. Available from: http://www.diseaseinfosearch.org/result/5121 PubMed PMID: 6413594. doi: 10.1093/infdis/148.3.369. [Google Scholar]
Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology.. Methods Mol Biol 2012;799:1-20. Available from: http://europepmc.org/abstract/MED/21993636 PubMed PMID: 21993636. doi: 10.1007/978-1-61779-346-2_1. [Google Scholar]
D' Agati VC, Marangoni BA. The Waterhouse-Friderichsen Syndrome. N Engl J Med 1945 Jan;232(1):1-7. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM194501042320101 doi: 10.1056/NEJM194501042320101. [Google Scholar]
Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine 2012;30:10-1016. doi: 10.1016/j.vaccine. [Google Scholar]
Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr 2013;11(1):17-1186. Available from: http://pophealthmetrics.biomedcentral.com/articles/10.1186/1478-7954-11-17 PubMed PMID: 24016339. doi: 10.1186/1478-7954-11-17. [Google Scholar]
Chang Q, Tzeng Y, Stephens DS. Meningococcal disease: changes in epidemiology and prevention. Clin Epidemiol 2012;4:237-245. Available from: http://dx.doi.org/10.2147/CLEP.S28410 PubMed PMID: 23071402. doi: 10.2147/CLEP.S28410. [Google Scholar]
Dwilow R, Fanella S. Invasive Meningococcal Disease in the 21st Century-An Update for the Clinician 2015. Curr Neurol Neurosci Rep 2015;15(3):2. Available from: http://hivinsite.ucsf.edu/InSite?page=kb-03-01-08 PubMed PMID: 25637287. doi: 10.1007/s11910-015-0524-6. [Google Scholar]
Abio A, Neal KR, Beck CR. An epidemiological review of changes in meningococcal biology during the last 100 years. Pathog Glob Health 2013 Dec;107(7):373-380. Available from: http://europepmc.org/abstract/MED/24392681 PubMed PMID: 24392681. doi: 10.1179/2047773213Y.0000000119. [Google Scholar]
Al-Tawfiq JA, Clark TA, Memish ZA. Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology.. J Travel Med 2010;17 Suppl:3-8. Available from: http://jtm.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=20849427 PubMed PMID: 20849427. doi: 10.1111/j.1708-8305.2010.00448.x. [Google Scholar]
Bermal N, Huang LM, Dubey AP, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Human Vaccines 2011;7(2):239-247. Available from: http://www.tandfonline.com/doi/abs/10.4161/hv.7.2.14068 doi: 10.4161/hv.7.2.14068. [Google Scholar]
European Centre for Disease Prevention and Control (ECDC . Surveillance of invasive bacterial diseases in Europe. ECDC 2011;URL [cited 2014 May 28]. Available from: http://www.ecdc.europa.eu/en/publications/Publications/invasive [Google Scholar]
Istituto Superiore di Sanità (ISS). Gruppo di Lavoro del centro nazionale di epidemiologia, sorveglianza e promozione della salute (CNEPS) Dati e evidenze disponibili per l'introduzione della vaccinazione antimeningococco B nei nuovi nati e negli adolescenti. June 2014. Available at: http://www.epicentro.iss.it/temi/vaccinazioni/pdf/Istruttoria%20MENINGOCOCCO%20B.Pdf.
Panatto D, Amicizia D, Lai PL, et al. New versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers. Indian J Med Res 2013;138:835. [Google Scholar]
Lewis LA, Ram S. Meningococcal disease and the complement system.. Virulence 2013 Oct;5(1):98-126. Available from: http://europepmc.org/abstract/MED/24104403 PubMed PMID: 24104403. doi: 10.4161/viru.26515. [Google Scholar]
European Centre for Disease Prevention and Control (ECDC) , author. Annual epidemiological report 2014 – Vaccine-preventable diseases – invasive bacterial diseases.
Azzari C, Canessa C, Lippi F, Moriondo M, Indolfi G, Nieddu F, et al. Distribution of invasive meningococcal B disease in Italian pediatric population: Implications for vaccination timing. Vaccine 2014;32(10):1187-1191. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264410X1301325X PubMed PMID: 24120548. doi: 10.1016/j.vaccine.2013.09.055. [Google Scholar]
Centers for Disease Control and Prevention (CDC) , author. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2011. 2012. Available via the Internet: http://www.cdc.gov/abcs/reports-findings/survreports/mening11.pdf.
Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis.. Vaccine 2009 May;27 Suppl 2. Available from: http://europepmc.org/abstract/MED/19477055 PubMed PMID: 19477055. doi: 10.1016/j.vaccine.2009.04.070. [Google Scholar]
Guzzetta G, Manfredi P, Gasparini R, Panatto D, Edmunds WJ. On the relationship between meningococcal transmission dynamics and disease: remarks on humoral immunity.. Vaccine 2009 Jan;27(25-26):3429-3434. Available from: https://www.nlm.nih.gov/medlineplus/meningococcalinfections.html PubMed PMID: 19460601. doi: 10.1016/j.vaccine.2009.01.092. [Google Scholar]
Trotter CL, Maiden MCJ. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009;8(7):851-861. Available from: http://europepmc.org/abstract/MED/19538112 PubMed PMID: 19538112. doi: 10.1586/erv.09.48. [Google Scholar]
Caugant DA, Maiden MCJ. Meningococcal carriage and disease--population biology and evolution.. Vaccine 2009 May;27 Suppl 2. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264-410X(09)00615-X PubMed PMID: 19464092. doi: 10.1016/j.vaccine.2009.04.061. [Google Scholar]
Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010;10(12):853-861. Available from: http://www.scholaruniverse.com/ncbi-linkout?id=21075057 PubMed PMID: 21075057. doi: 10.1016/S1473-3099(10)70251-6. [Google Scholar]
Maiden MCJ, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity.. J Infect Dis 2008;197(5):737-743. Available from: http://www.jid.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=18271745 PubMed PMID: 18271745. doi: 10.1086/527401. [Google Scholar]
Gasparini R, Comanducci M, Amicizia D, Ansaldi F, Canepa P, Orsi A, et al. Molecular and serological diversity of Neisseria meningitidis carrier strains isolated from Italian students aged 14 to 22 years.. J Clin Microbiol 2014 Mar;52(6):1901-1910. Available from: http://jcm.asm.org/cgi/pmidlookup?view=long&pmid=24648565 PubMed PMID: 24648565. doi: 10.1128/JCM.03584-13. [Google Scholar]
Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis.. Vaccine 2009 May;27 Suppl 2. Available from: http://europepmc.org/abstract/MED/19477055 PubMed PMID: 19477055. doi:
1016/j.vaccine.2009.04.070. [Google Scholar]
Kristiansen PA, Ba AK, Ouédraogo A, Sanou I, Ouédraogo R, Sangaré L, et al. Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac.. BMC Infect Dis 2014 Dec;14:663-14. Available from: http://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-014-0663-4 PubMed PMID: 25472422. doi: 10.1186/s12879-014-0663-4. [Google Scholar]
Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014;384(9960):2123-2131. Available from: http://ClinicalTrials.gov/search/term=25145775%20%5BPUBMED-IDS%5D PubMed PMID: 25145775. doi: 10.1016/S0140-6736(14)60842-4. [Google Scholar]
Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nature reviews. Immunology 2009;9(3):213-220. Available from: https://www.nlm.nih.gov/medlineplus/bacterialinfections.html PubMed PMID: 19214194. doi: 10.1038/nri2494. [Google Scholar]